The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
Park National Corporation
PRK · NYSE American · USD · Market cap $3.3B · 1,589 employees
Park National Corporation operates as the bank holding company for Park National Bank that provides commercial banking and trust services in small and medium population areas in the United States.
FAIL · Does not pass the screenPrice as of 27 Oct 2026Daily close, not a live quote
Screened 2026-10-27 · the tape above runs as of 20:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price181.99 USD at the 27 Oct 2026 close
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.00)
- Last reviewed27 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 181.99 against the desk's fair-value range, base estimate 201.49, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.00, read 2026-10-25
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Park National Corporation holds its Accumulation at $181.99. The statistical read favours the buyers, held for 1 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the buyers, held for 1 days |
| Price at the screen | $181.99 |
| Valuation | 16.26 trailing · 13.69 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.71 |
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: bank
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited keyword in sector/industry: bank | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Park National does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PRK's ethical verdict changes
Today PRK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. A 10.7% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus Hold. The average target sits +12% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy This Regional Bank Fails Our Screen
Everyday deposits from Ohio workshops and Midwest farms still flow through old-school regional banks like this one. Park National handles the basics well enough, yet the numbers show little edge worth chasing at the current price. Revenue growth of 21 percent and a 31 percent profit margin sit alongside a forward P/E of 14.9 times and return on equity of just 12 percent, while shares trade a shade above our fair value with a negative margin of safety.
We pass for the clearest reason first. The ethical screen flags any bank exposure outright, and that rule is non-negotiable here. On top of that the opportunity rating sits at none, analyst targets cluster below the market price, and nothing in the reported metrics suggests the business clears our bar once the sector screen is applied.
Valuation looks ordinary rather than cheap, and cyclical earnings in regional banking can flatten fast when rates or local economies turn. The unknown moat adds another layer of uncertainty that does not justify stretching the rules. Analysis, not advice.
| Forward P/E | 13.7xcheap for a company growing this fast |
| Trailing P/E | 16.3xreasonably valued |
| EPS, trailing | 11.19 |
| EPS, forward | 13.30 |
| Revenue growth | +25.7%strong top-line growth |
| Profit margin | 31.3%highly profitable on every dollar of sales |
| Return on equity | 12.6%a solid return on shareholder capital |
| Dividend yield | 241.00% |
| Beta | 0.71steadier than the market |
| Short interest, float | 0.05% |
| 52-week range | 149.06 - 215.00 |
| Market cap | $3.3B |
| Employees | 1,589 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePRK trades on NYSE American. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (3 analysts) rates it none, with a mean price target of $184.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- 1st Source (SRCE) Q3 Earnings and Revenues Top Estimates Yahoo Finance · 6d ago
- First Busey (BUSE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Yahoo Finance · 8d ago
- Park National (PRK) to Report Q3 Results: Wall Street Expects Earnings Growth Yahoo Finance · 9d ago
- Park National (PRK) Stock May Be 29% Undervalued On Equity Returns Yahoo Finance · 11d ago
- Here's Why Park National (PRK) is a Great Momentum Stock to Buy Zacks · 5 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $169.11 | +4.4% | $1.10 | $1,051 | +5.1% |
| 2 months | $171.54 | +2.9% | $1.10 | $1,036 | +3.6% |
| 3 months | $156.74 | +12.6% | $1.10 | $1,133 | +13.3% |
| 6 months | $161.71 | +9.2% | $2.20 | $1,106 | +10.6% |
| 1 year | $160.07 | +10.3% | $5.59 | $1,138 | +13.8% |
| 2 years | $125.65 | +40.5% | $10.35 | $1,488 | +48.8% |
| 3 years | $99.21 | +78.0% | $14.57 | $1,926 | +92.6% |
| 5 years | $105.64 | +67.1% | $23.59 | $1,895 | +89.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PRK does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.